Journal: Thoracic Cancer
Article Title: Galectin‐3 enhances trastuzumab resistance by regulating cancer malignancy and stemness in HER2 ‐positive breast cancer cells
doi: 10.1111/1759-7714.14474
Figure Lengend Snippet: Galectin‐3 promoted cancer malignancy of HER2‐positive breast cancer cells. Western blot analysis of galectin‐3, HER2, and β‐actin in (a) pcDNA‐NC, pcDNA‐ LGALS3 , SKBR3, and SKBR3 cells treated with 100 ng/mL r‐Gal3 for 3 days; (b) JIMT1 cells transfected with siRNA‐NC, siRNA‐533, or siRNA‐571; and (c) JIMT1 cells treated with 0, 10, or 20 μg/mL GB1107 for 3 days. Cell viability curves for (d) pcDNA‐NC, pcDNA‐ LGALS3 , SKBR3, and SKBR3 cells treated with 100 ng/mL r‐Gal3 for 3 days; and (e) siRNA‐NC, siRNA‐533, siRNA‐571, and JIMT1 cells treated with 10 μg/mL GB1107 for 3 days. (f) Healing assays; (g) colony formation assays; and (h) transwell assays in pcDNA‐NC, pcDNA‐ LGALS3 , siRNA‐NC, and siRNA‐533 cells. The significant differences are indicated by asterisk (* p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001)
Article Snippet: Recombinant galectin‐3 (r‐Gal3) was obtained from PeproTech.
Techniques: Western Blot, Transfection